RECQL and cancer: Given the sensitivity of RECQ1-deficient cells to MMS, we first examined whether RECQ1 expression is upregulated at the mRNA level after treatment with clinically relevant alkylating agents Temozolomide (TMZ) and Fotemustine (FMS), both of which are used as cancer chemotherapeutics [48].